Cargando…
Is the newest angiotensin‐receptor blocker azilsartan medoxomil more efficacious in lowering blood pressure than the older ones? A systematic review and network meta‐analysis
Angiotensin‐receptor blockers are often considered insufficiently efficacious in reducing blood pressure. However, newer angiotensin‐receptor blockers may be more effective than the older ones. A network meta‐analysis was performed to compare the efficacy of various angiotensin‐receptor blockers in...
Autores principales: | Wang, Ji‐Guang, Zhang, Miao, Feng, Ying‐Qing, Ma, Chang‐Sheng, Wang, Tzung‐Dau, Zhu, Zhi‐Ming, Kario, Kazuomi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8678765/ https://www.ncbi.nlm.nih.gov/pubmed/33609077 http://dx.doi.org/10.1111/jch.14227 |
Ejemplares similares
-
Efficacy and safety of azilsartan medoxomil, an angiotensin receptor blocker, in Korean patients with essential hypertension
por: Juhasz, Attila, et al.
Publicado: (2018) -
Evaluation of the angiotensin II receptor blocker azilsartan medoxomil in African‐American patients with hypertension
por: Johnson, Wallace, et al.
Publicado: (2017) -
Antihypertensive efficacy of the angiotensin receptor blocker azilsartan medoxomil compared with the angiotensin-converting enzyme inhibitor ramipril
por: Bönner, G, et al.
Publicado: (2013) -
COVID‐19 and hypertension—evidence and practical management: Guidance from the HOPE Asia Network
por: Kario, Kazuomi, et al.
Publicado: (2020) -
Insights on home blood pressure monitoring in Asia: Expert perspectives from 10 countries/regions
por: Wang, Ji‐Guang, et al.
Publicado: (2020)